vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and HUTCHMED (China) Ltd (HCM). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $270.8M, roughly 1.0× HUTCHMED (China) Ltd). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 0.7%, a 95.6% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -16.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
ACAD vs HCM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $270.8M |
| Net Profit | $273.6M | $2.0M |
| Gross Margin | 90.8% | 37.7% |
| Operating Margin | 6.1% | -13.2% |
| Net Margin | 96.3% | 0.7% |
| Revenue YoY | 9.4% | -16.5% |
| Net Profit YoY | 90.3% | -83.6% |
| EPS (diluted) | $1.61 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $270.8M | ||
| Q3 25 | $278.6M | — | ||
| Q2 25 | $264.6M | $277.7M | ||
| Q1 25 | $244.3M | $324.5M | ||
| Q4 24 | $259.6M | — | ||
| Q3 24 | $250.4M | — | ||
| Q2 24 | $242.0M | $305.7M | ||
| Q1 24 | $205.8M | — |
| Q4 25 | $273.6M | $2.0M | ||
| Q3 25 | $71.8M | — | ||
| Q2 25 | $26.7M | $455.0M | ||
| Q1 25 | $19.0M | $11.9M | ||
| Q4 24 | $143.7M | — | ||
| Q3 24 | $32.8M | — | ||
| Q2 24 | $33.4M | $25.8M | ||
| Q1 24 | $16.6M | — |
| Q4 25 | 90.8% | 37.7% | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | 0.1% | ||
| Q1 25 | 91.7% | 48.0% | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | 41.1% | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | -13.2% | ||
| Q3 25 | 12.8% | — | ||
| Q2 25 | 12.2% | -1.3% | ||
| Q1 25 | 7.9% | -5.0% | ||
| Q4 24 | 59.1% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 12.6% | -9.0% | ||
| Q1 24 | 7.4% | — |
| Q4 25 | 96.3% | 0.7% | ||
| Q3 25 | 25.8% | — | ||
| Q2 25 | 10.1% | 163.8% | ||
| Q1 25 | 7.8% | 3.7% | ||
| Q4 24 | 55.4% | — | ||
| Q3 24 | 13.1% | — | ||
| Q2 24 | 13.8% | 8.4% | ||
| Q1 24 | 8.0% | — |
| Q4 25 | $1.61 | $0.00 | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.16 | $0.52 | ||
| Q1 25 | $0.11 | $0.01 | ||
| Q4 24 | $0.86 | — | ||
| Q3 24 | $0.20 | — | ||
| Q2 24 | $0.20 | $0.03 | ||
| Q1 24 | $0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $1.4B |
| Total DebtLower is stronger | — | $93.2M |
| Stockholders' EquityBook value | $1.2B | $1.2B |
| Total Assets | $1.6B | $1.8B |
| Debt / EquityLower = less leverage | — | 0.08× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $1.4B | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | $1.4B | ||
| Q1 25 | $217.7M | $836.1M | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | $802.5M | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | $93.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $93.4M | ||
| Q1 25 | — | $82.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $82.1M | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $917.3M | — | ||
| Q2 25 | $822.4M | $1.2B | ||
| Q1 25 | $765.2M | $759.9M | ||
| Q4 24 | $732.8M | — | ||
| Q3 24 | $577.2M | — | ||
| Q2 24 | $516.7M | $740.1M | ||
| Q1 24 | $464.0M | — |
| Q4 25 | $1.6B | $1.8B | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $1.8B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $976.9M | — | ||
| Q2 24 | $914.1M | $1.3B | ||
| Q1 24 | $855.1M | — |
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.08× | ||
| Q1 25 | — | 0.11× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $8.2M |
| Free Cash FlowOCF − Capex | — | $3.4M |
| FCF MarginFCF / Revenue | — | 1.2% |
| Capex IntensityCapex / Revenue | — | 1.8% |
| Cash ConversionOCF / Net Profit | -0.18× | 4.21× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-96.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $8.2M | ||
| Q3 25 | $74.3M | — | ||
| Q2 25 | $64.0M | $-72.9M | ||
| Q1 25 | $20.3M | $40.3M | ||
| Q4 24 | $40.4M | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | $25.0M | $-39.8M | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | $3.4M | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | $-82.2M | ||
| Q1 25 | — | $32.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | $-49.9M | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.2% | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | 10.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | -16.3% | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.8% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | 3.3% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | 3.3% | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 4.21× | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 2.40× | -0.16× | ||
| Q1 25 | 1.07× | 3.38× | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | -1.54× | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
HCM
Segment breakdown not available.
